METHOD FOR DETECTING PATHOGENS USING MICROBEADS CONJUGATED TO BIORECOGNITION MOLECULES

• US 20100021937A1
• Filed: 02/13/2007
• Published: 01/28/2010
• Est. Priority Date: 02/15/2006
• Status: Abandoned Application

• Current Assignee: Fio Corporation
• Original Assignee: Fio Corporation
• Inventors: Greenberg, Michael Mordinson, Chan, Warren Che Wor, Kain, Kevin Charles
• Application Number:
  US12/279,639
• Publication Number:
  US 20100021937A1
• Time in Patent Office: Days
• US Class Current: 435/7.200
• CPC Class Codes: B01L 2200/10 Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
• CPC Class Codes: B01L 2300/02 Identification, exchange or storage of information
• CPC Class Codes: B01L 2300/025 Displaying results or values with integrated means
• CPC Class Codes: B01L 2300/0627 Sensor or part of a sensor is integrated
• CPC Class Codes: B01L 3/5027 by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip B01L3/5023 takes precedence; micromixers B01F33/30; microreactors for synthesis B01J19/0093; microcapillary devices in general B81B1/00
• CPC Class Codes: B01L 3/502715 characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
• CPC Class Codes: B82Y 15/00 Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• CPC Class Codes: C12Q 1/04 Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor C12Q1/6897 takes precedence
• CPC Class Codes: G01N 21/6428 Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" in vivo A61B5/00; immunoassay G01N33/53
• CPC Class Codes: G01N 21/6489 Photoluminescence of semiconductors
• CPC Class Codes: G01N 33/569 for microorganisms, e.g. protozoa, bacteria, viruses
• CPC Class Codes: G01N 33/588 with semiconductor nanocrystal label, e.g. quantum dots
• CPC Class Codes: G06F 16/29 Geographical information databases
• CPC Class Codes: G16H 50/20 for computer-aided diagnosis, e.g. based on medical expert systems
• CPC Class Codes: G16Z 99/00 Subject matter not provided for in other main groups of this subclass
• CPC Class Codes: H04W 4/021 Services related to particular areas, e.g. point of interest [POI] services, venue services or geofences
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

A method and system are provided for the simultaneous detection and identification of multiple pathogens in a patient sample. The sample is combined with microbeads, which have been injected with quantum dots or fluorescent dye and conjugated to pathogen-specific biorecognition molecules, such as antibodies and oligonucleotides. Treatment options may be determined based on the identities of the pathogens detected in the sample.

Claims

1. A method of detecting one or more pathogens, identifying one or more pathogens, characterizing one or more pathogens or characterizing a pathogen host, said method being for use with a clinical sample collected from a host that potentially contains one or more target molecules, said method comprising the steps of:

a detection medium providing step of providing a detection medium containing pathogen-specific/host marker identification complexes for respective detection of pathogens and host markers, wherein said pathogen-specific/host marker identification complexes comprise microbeads conjugated to respective pathogen-specific/host marker biorecognition molecules (BRMs), and wherein each of said microbeads contains quantum dots, fluorescent dyes, or combinations thereof, such that each of said microbeads is adapted to emit one or more spectra as a first signal;

a detection complex forming step of combining said clinical sample with said detection medium and detection molecules, with both said pathogen-specific/host marker identification complexes and said detection molecules being adapted to bind with said target molecules if present in the clinical sample, to generate detection complexes, wherein each of said detection molecules is further adapted to emit one or more spectra as a second signal;

a spectral reference database providing step of providing a spectral reference database of pathogen-specific/host marker reference spectra;

an analysis step of;

(i) flowing said detection complexes, under influence of flow forces, through a microfluidic channel and a laser beam, such that resulting spectral signals are emitted from different types of said detection complexes, with said resulting spectral signals comprising said first signal, said second signal, or a combination thereof; and

(ii) analyzing said resulting spectral signals with a detection element in a handheld diagnostic device by;

(a) detecting said resulting spectral signals;

(b) collecting and translating said resulting spectral signals, into a translated optical code for each of said different types of detection complexes, using solid state photodetectors of said detection element which are adapted to emit electrons in direct response to said resulting spectral signals; and

(c) matching each said translated optical code with a corresponding one of said pathogen-specific/host marker specific spectra in said spectral reference database to produce a list of pathogens contained within the clinical sample, and a list of pathogen/host characteristics.

2. The method of claim 1 for use with a blood sample, a plasma sample, CSF (Cerebrospinal Fluid), a serum sample, BAL (Bronchoalveolar lavage), NP (nasopharyngeal) swabs, NP aspirates, or sputum as the clinical sample.

3. The method of claim 1, wherein said solid state photodetectors comprise a collection of Avalanche Photodetectors.

4. The method of claim 3, wherein said collection of Avalanche Photodetectors is arranged in series.

5. The method of claim 1, wherein each of said microbeads contains a unique combination of said quantum dots, based on color and/or intensity of said quantum dots, for emission of a unique spectrum as said first signal for each of said pathogen-specific/host marker identification complexes.

6. The method of claim 1, wherein said detection complexes identify said pathogen/host characteristics by said resulting spectral signals in the form of the combination of said first signal and said second signal emitted by said detection molecules.

7. The method of claim 1, wherein at least one of said detection molecules comprises a fluorophore to emit said second signal.

8. The method of claim 7, wherein said fluorophore is conjugated to an anti-human IgG molecule, an anti-human IgM molecule, an anti-pathogen/host marker detection antibody, or an oligonucleotide sequence.

9. The method of claim 1, wherein, in said analysis step, analysis of said resulting spectral signals is additionally performed by:

a combined spectrophotometer/CCD (Charge-coupled Device) system, a photomultiplier tube, or a combination thereof.

10. The method of claim 1, wherein said microfluidic channel comprises a PDMS (polydimethylsiloxane) cast channel which is plasma treated, and bound to a glass slide.

11. The method of claim 1, wherein said flow forces are either electrokinetic or hydrodynamic forces.

12. The method of claim 1, wherein said spectral reference database is located on-board the diagnostic device.

13. The method of claim 1, further comprising a geographic location collection step of collecting geographic location data from said diagnostic device for at least one of said pathogens and said host.

14. The method of claim 13, wherein said geographic location data is collected via a GPS-enabled (Global Positioning System) element within the diagnostic device.

15. The method of claim 1, further comprising:

a geographic location determining step of determining geographic location data for said diagnostic device and for at least one of said pathogens and said host;

a remote database providing step of providing, at a location geographically remote from said diagnostic device, a remote database;

a transmission step of wirelessly transmitting, to said remote database, said list of pathogens contained within said clinical sample, said list of pathogen/host characteristics, and said geographic location data; and

a reception step of receiving, collating and storing, in said remote database, said list of pathogens contained within said clinical sample, together with said list of pathogen/host characteristics, and together with said geographic location data, for each said transmission step of each said diagnostic device.

16. The method of claim 1, further including an additional step of providing a list of treatment options based on the list of pathogens contained within said clinical sample.

17. The method of claim 1, wherein the detection medium contains at least three said identification complexes, each for detection of a different one of said pathogens and said host markers.

18. The method of claim 1, wherein the identification complexes are for detection of HIV, Hepatitis B and Hepatitis C.

19. The method of claim 1, wherein the identification complexes are for detection of HIV, Hepatitis B, Hepatitis C, malaria and Dengue virus.

20. A system for detecting pathogens, identifying pathogens, characterizing pathogens or characterizing pathogen hosts, said system being for use with a clinical sample collected from a host that potentially contains one or more target molecules, and being for use with detection molecules adapted to bind with said target molecules if present in the clinical sample and emit one or more spectra as a second signal, said system comprising:

a) a detection medium containing pathogen-specific/host marker identification complexes for respective detection of pathogens and host markers, wherein said pathogen-specific/host marker identification complexes comprise microbeads conjugated to respective pathogen-specific/host marker biorecognition molecules (BRMs), and wherein each of said microbeads contains quantum dots, fluorescent dyes, or combinations thereof, such that each of said microbeads is adapted to emit one or more spectra as a first signal, with said detection medium operative to be combined with the clinical sample and with said detection molecules, with said pathogen-specific/host marker identification complexes adapted to bind with said target molecules if present in the clinical sample, such that said pathogen-specific/host marker identification complexes, said detection molecules, and said target molecules form detection complexes;

b) a handheld diagnostic device, including;

i) a microfluidic platform that is operative to drive the detection complexes, using flow forces, through a laser-illuminated region in a microfluidic channel, such that resulting spectral signals are emitted from different types of said detection complexes, with said resulting spectral signals including said first signal, said second signal, or a combination thereof; and

ii) a detection element that is operative to detect said resulting spectral signals, and having solid state photodetectors adapted to collect and translate said resulting spectral signals, by emission of electrons in direct response to said resulting spectral signals, into a translated optical code for each of said different types of detection complexes; and

c) a spectral reference database of pathogen-specific/host marker reference spectra operative to match each said translated optical code with a corresponding one of said pathogen-specific/host marker specific spectra in said spectral reference database to generate a list of pathogens contained within the clinical sample, and a list of pathogen/host characteristics.

21. The system of claim 20, wherein at least one of said microbeads contains quantum dots to provide said first signal, and wherein said system is for use with a blood sample, a plasma sample, CSF (Cerebrospinal Fluid), a serum sample, a BAL (Bronchoalveolar lavage), a NP (nasopharyngeal) swab, a NP aspirate, or a sputum sample as the clinical sample.

22. The system of claim 20, wherein each of said microbeads contains a unique combination of said quantum dots for emission of a unique spectrum as said first signal for each of said pathogen-specific/host marker identification complexes.

23. The system of claim 20, for use with a signal generating molecule as a constituent of at least one of said detection molecules, with said signal generating molecule operatively emitting said second signal.

24. The system of claim 23, for use with a fluorophore as said signal generating molecule.

25. The system of claim 24, for use with an anti-human IgG molecule, an anti-human IgM molecule, an anti-pathogen/host marker detection antibody, or an oligonucleotide sequence, conjugated to said fluorophore.

26. The system of claim 20, wherein said solid state photodetectors comprise a collection of Avalanche Photodetectors.

27. The system of claim 26, wherein said collection of Avalanche Photodetectors is arranged in series.

28. The system of claim 20, wherein said detection element comprises a spectrometer/CCD (Charge-coupled Device) system, a photomultiplier tube, or a combination thereof, for additional analysis of said resulting spectral signals.

29. The system of claim 20, wherein said diagnostic device is operative to display a list of treatment options based on the list of pathogens generated.

30. The system of claim 20, further including a laser operative to illuminate said laser-illuminated region in said microfluidic channel.

31. The system of claim 20, wherein said microfluidic channel comprises a PDMS (polydimethylsiloxane) cast channel which is plasma treated, and bound to a glass slide.

32. The system of claim 20, wherein said flow forces are either electrokinetic or hydrodynamic forces.

33. The system of claim 20, wherein said detection element includes a filter operative to direct said resulting spectral signals to said solid state photodetectors, to a spectrometer, to a photomultiplier tube, or to a combination thereof.

34. The system of claim 20, wherein said spectral reference database is on-board the diagnostic device.

35. The system of claim 20, further comprising a remote database containing data concerning different pathogens and data concerning pathogen/host characteristics, and a connection on said diagnostic device to enable communication with said remote database.

36. The system of claim 35, wherein said connection to said remote database is provided by a wireless communications network.

37. The system of claim 35, wherein said connection comprises a transmission element operative to transmit said list of pathogens and/or said list of pathogen/host characteristics to said remote database.

38. The system of claim 37, wherein said transmitter is operative to automatically initiate transmission to said remote database upon generation of said list of pathogens and/or said list of pathogen/host characteristics.

39. The system of claim 20, wherein the diagnostic device further comprises a GPS (Global Positioning System) locator element to provide geographic location data associated with said clinical sample.

40. The system of claim 20, further comprising:

a locator element operative to determine geographic location data for said diagnostic device and for at least one of said pathogens and said host;

a remote database provided at a location geographically remote from said diagnostic device; and

a wireless transmission element operative to wirelessly transmit, to said remote database, said data concerning pathogens contained within said clinical sample, said data concerning pathogen/host characteristics, and said geographic location data; and

a wireless reception element operative to receive, collate and store, in said remote database, said data concerning pathogens contained within said clinical sample, together with said data concerning pathogen/host characteristics, and together with said geographic location data, for each wireless transmission from each said diagnostic device.

41. The system of claim 40, wherein said locator element comprises a GPS (Global Positioning System) locator element to determine said geographic location data.

42. The system of claim 20, wherein said identification complexes are provided as one or more lyophilized powders.

43. The system of claim 20, wherein said BRMs comprise native, recombinant or synthetic pathogen and host specific antibodies or antigens or oligonucleotides complementary to pathogen or host genes of interest, or a combination thereof.

44. The system of claim 20, wherein the detection medium contains at least three said identification complexes, each for detection of a different one of said pathogens and said host markers.

45. The system of claim 20, wherein the identification complexes are for detection of HIV, Hepatitis B and Hepatitis C.

46. The system of claim 20, wherein the identification complexes are for detection of HIV, Hepatitis B, Hepatitis C, malaria and Dengue virus.

47. The system of claim 20, for use with a lyophilized powder as at least one of said detection molecules.